Resource use tables for economic evaluation

Nicholas James; Sarah Pirrie; Ann Pope; Darren Barton; Lazaros Andronis; Ilias Goranitis; Stuart Collins; Duncan McLaren; Joe O’Sullivan; Chris Parker; Emilio Porfiri; John Staffurth; Andrew Stanley; James Wylie; Sharon Beesley; Alison Birtle; Janet Brown; Prabir Chakraborti; Martin Russell; Lucinda Billingham

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

James N, Pirrie S, Pope A, et al. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Southampton (UK): NIHR Journals Library; 2016 Jul. (Health Technology Assessment, No. 20.53.)

$Cover of TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer$

TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.

Show details

Contents

< Prev Next >

Appendix 6Resource use tables for economic evaluation

TABLE 95

Number (percentage) of people who received a treatment and average use for ZA and no ZA

Treatment/service	ZA			No ZA
Treatment/service	n	%	Mean no. of cycles/units used	n	%	Mean no. of cycles/units used
Trial treatments
Docetaxel + prednisolone	342	98	6.31	349	98	6.11
ZA	342	98	6.13	0	0	0.00
Sr-89	125	36	1.00	120	34	1.00
ZA as follow-up treatment	192	55	5.11	1	0	3.00
Concomitant medications
Radiotherapy	177	51	1.65	204	57	1.95
Abiraterone	56	16	1.00	68	19	1.00
ZA as concomitant medication	73	21	3.77	63	18	1.94
Sr-89 as concomitant medication	15	4	1.00	21	6	1.00
Blood transfusion	31	9	2.10	22	6	2.50
Cabazitaxel	18	5	1.56	12	3	2.33
Docetaxel as concomitant medication	34	10	2.94	38	11	3.13
Mitoxantrone	23	7	2.30	15	4	1.87
Surgery	18	5	1.20	5	1	1.17
Outpatient appointments and inpatient stay
Hospital outpatient appointment	296	85	5.79	293	82	5.25
Hospital inpatient stay	231	66	8.00	250	70	8.28
GP appointments	311	89	5.03	328	92	5.61

: GP, general practitioner.

TABLE 96

Number (percentage) of people who received a treatment and average use for Sr-89 and no Sr-89

Treatment/service	Sr-89			No Sr-89
Treatment/service	n	%	Mean no. of cycles/units used	n	%	Mean no. of cycles/units used
Trial treatments
Docetaxel + prednisolone	345	99	6.23	346	97	6.19
ZA	172	49	6.14	170	48	6.12
Sr-89	245	70	1.00	0	0	0.00
ZA as follow-up treatment	90	26	5.10	103	29	5.10
Concomitant medications
Radiotherapy	184	53	1.67	197	55	1.94
Abiraterone	59	17	1.00	65	18	1.00
ZA as concomitant medication	61	17	2.85	75	21	2.97
Sr-89 as concomitant medication	16	5	1.13	20	6	1.00
Blood transfusion	26	7	2.31	27	8	2.22
Cabazitaxel	19	5	1.84	11	3	1.91
Docetaxel as concomitant medication	36	10	3.11	36	10	2.97
Mitoxantrone	20	6	2.00	18	5	2.28
Surgery	13	4	1.23	10	3	1.10
Outpatient appointments and inpatient stay
Hospital outpatient appointment	227	65	5.27	254	71	5.78
Hospital inpatient stay	295	84	8.52	294	82	7.80
GP appointments	311	89	5.10	328	92	5.55

: GP, general practitioner.

TABLE 97

Number of instances of radiotherapy

Number of instances of radiotherapy	No ZA	ZA	Total
0	153	173	326
1	108	114	222
2	42	39	81
3	29	10	39
4	12	8	20
5	9	3	12
6	3	1	4
8	1	1	2
9	0	1	1

TABLE 98

Total number of instances of radiotherapy

Number of instances of radiotherapy	No ZA	ZA
Total number of instances of radiotherapy	398	292

TABLE 99

Number of instances of radiotherapy

Number of instances of radiotherapy	No Sr-89	Sr-89	Total
0	160	166	326
1	111	111	222
2	36	45	81
3	25	14	39
4	12	8	20
5	8	4	12
6	2	2	4
8	2	0	2
9	1	0	1

TABLE 100

Total number of instances of radiotherapy

Number of instances of radiotherapy	No Sr-89	Sr-89
Total number of instances of radiotherapy	383	307

TABLE 101

Average number of instances of radiotherapy: no ZA

Average number of instances of radiotherapy	No ZA	ZA
For patients who had radiotherapy	1.95	1.65
For all patients in the group	1.11	0.83

TABLE 102

Average number of instances of radiotherapy: no Sr-89

Average number of instances of radiotherapy	No Sr-89	Sr-89
For patients who had radiotherapy	1.94	1.67
For all patients in the group	1.07	0.88

Copyright © Queen’s Printer and Controller of HMSO 2016. This work was produced by James et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK373594

Contents

< Prev Next >

PubReader
Print View
Cite this Page
James N, Pirrie S, Pope A, et al. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Southampton (UK): NIHR Journals Library; 2016 Jul. (Health Technology Assessment, No. 20.53.) Appendix 6, Resource use tables for economic evaluation.
PDF version of this title (11M)

Other titles in this collection

Health Technology Assessment

Recent Activity

Clear Turn Off Turn On

Resource use tables for economic evaluation - TRAPEZE: a randomised controlled t...
Resource use tables for economic evaluation - TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf